MPTP and parkinson's disease

Abstract Recognition of the biological effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a compound which is selectively toxic to the zona compacta of substantia nigra, has stimulated a renaissance of basic research in Parkinson's disease. Studies on the mechanism of action of this compound and its effects could greatly enhance our understanding of the role of dopamine and the nigrostriatal system, and are likely to expand our knowledge about basic cellular mechanisms of the substantia nigra in health and disease. MPTP has already led to the successful development of an animal model of Parkinson's disease in the primate and has generated increasing interest in the search for environmental causes of this disease. This broad and potentially exciting scenario still appears to be in its early stages.

[1]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[2]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[3]  S. Snyder,et al.  Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. , 1984, European journal of pharmacology.

[4]  C. Mytilineou,et al.  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon. , 1984, Science.

[5]  C. Ward,et al.  Parkinson's disease in 65 pairs of twins and in a set of quadruplets , 1983, Neurology.

[6]  P. Riederer,et al.  (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. , 1983, Modern problems of pharmacopsychiatry.

[7]  J. Langston,et al.  The importance of the ‘4–5’ double bond for neurotoxicity in primates of the pyridine derivative MPTP , 1984, Neuroscience Letters.

[8]  D. Calne,et al.  AETIOLOGY OF PARKINSON'S DISEASE , 1983, The Lancet.

[9]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[10]  P. Ballard,et al.  Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson’s Disease , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[11]  D. Jacobowitz,et al.  N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey. , 1984, Psychopharmacology bulletin.

[12]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[13]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[14]  C. Mitchell.  Nervous system toxicology , 1982 .

[15]  D. Jacobowitz,et al.  Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. , 1984, Psychopharmacology bulletin.

[16]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[17]  Langston Jw,et al.  Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983 .

[18]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[19]  J. Langston,et al.  Pargyline prevents MPTP-induced parkinsonism in primates. , 1984, Science.

[20]  L. Olson,et al.  Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. , 1984, European journal of pharmacology.

[21]  U. Bondesson,et al.  Melanin affinity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, an inducer of chronic parkinsonism in humans. , 2009, Acta pharmacologica et toxicologica.

[22]  N. Bodor,et al.  Site-specific, sustained release of drugs to the brain. , 1981, Science.

[23]  W. Becker.  [The effect of the exocrine secretion of the pancreas on blood sugar regulation. I. Research after ligation of the pancreatic duct, after subtotal pancreatic resection, and after extensive destruction of the pancreas]. , 1958, Acta neurovegetativa.

[24]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[25]  J. Langston,et al.  1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra , 1984, Neuroscience Letters.